PPP6C

Serine/threonine-protein phosphatase 6 catalytic subunit · O00743 · PPP6C on Sugi Atlas →

1,965 patent compounds predicted against PPP6C, 1,745 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Calyculin A (SCHEMBL82924)	1.00	1/20
Calyculin A (SCHEMBL82925)	1.00	1/20
Okadaic Acid (SCHEMBL131485)	1.00	1/20
Molibresib (SCHEMBL1872390)	1.00	1/20
Okadaic Acid (SCHEMBL2386832)	1.00	1/20
Calyculin A (SCHEMBL4295478)	1.00	1/20
Calyculin A (SCHEMBL4299349)	1.00	1/20
Molibresib (SCHEMBL12671490)	1.00	1/20
Molibresib (SCHEMBL12966358)	1.00	1/20
Okadaic Acid (SCHEMBL544727)	0.99	1/20
Okadaic Acid (SCHEMBL545387)	0.99	1/20
Okadaic Acid (SCHEMBL545397)	0.99	1/20
Okadaic Acid (SCHEMBL4446706)	0.99	1/20
Okadaic Acid (SCHEMBL3390447)	0.97	1/20
SCHEMBL15919331	0.91	1/20
SCHEMBL9998851	0.91	1/20
Calyculin (SCHEMBL1443597)	0.89	1/20
Calyculin (SCHEMBL4291014)	0.89	1/20
Calyculin (SCHEMBL4298101)	0.89	1/20
SCHEMBL14756282	0.88	1/20

Clinical trials — most relevant to PPP6C by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	PHASE4	COMPLETED
Lithium for Prevention of Cognitive Declining in Mood Illnesses	PHASE4	NOT_YET_RECRUITING
Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus	PHASE2/PHASE3	UNKNOWN
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC	PHASE2	COMPLETED
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer	PHASE2	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas	nan	NOT_YET_RECRUITING
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PPP6C binder may also engage these)

Protein	Name	Similarity
Q64620	—	1.000	Q64620 →
Q9CQR6	—	1.000	Q9CQR6 →
Q27884	—	1.000	Q27884 →
Q9XZE5	—	1.000	Q9XZE5 →
P48528	—	1.000	P48528 →
P36614	—	1.000	P36614 →
P63330	—	1.000	P63330 →
A2XN40	—	1.000	A2XN40 →
P48463	—	1.000	P48463 →
PPP2CA	Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform	1.000	landscape →
P23696	—	0.999	P23696 →
Q07100	—	0.999	Q07100 →
P23778	—	0.998	P23778 →
Q8LSN3	—	0.998	Q8LSN3 →
Q9SX52	—	0.998	Q9SX52 →
Q10BT5	—	0.998	Q10BT5 →
P11084	—	0.998	P11084 →
A6H772	—	0.997	A6H772 →
PPP4C	Serine/threonine-protein phosphatase 4 catalytic subunit	0.997	landscape →
O04951	—	0.997	O04951 →
Q54RD6	—	0.997	Q54RD6 →
P48578	—	0.997	P48578 →
Q9Y0B7	—	0.997	Q9Y0B7 →
Q5BJ92	—	0.997	Q5BJ92 →
Q0E2S4	—	0.997	Q0E2S4 →
P48580	—	0.996	P48580 →
P20604	—	0.996	P20604 →
Q5R6K8	—	0.996	Q5R6K8 →
P11611	—	0.996	P11611 →
P97470	—	0.996	P97470 →